Skip to content
value.today
Evolus, Inc. logo

Evolus, Inc.

EOLS
$501 Mmarket cap on Oct 16, 2026-15.4% since Jan 2024
1D
-2.3%
Compare
World rank
#12,552
Revenue
$297 M
For year ending December-2025
Net income
$-52 M
-17.4% margin
SEC filing
Employees
334
As of December 31, 2025
SEC filing

Evolus, Inc. in brief

Evolus, Inc. is a listed company in the Pharmaceutical industry, based in Newport Beach, California, USA. It was founded in 2012. Its market value was $501 M on 16 October 2026, which makes it the 12,552nd largest listed company in the world and the 2,533rd largest in the USA on this site. In the year to December 2025 it had sales of $297 M and a net loss of $52 M. It employs about 334 people. Its largest product and service lines by sales in 2025 were Jeuveau (92%) and Evolysse (8%). Its shares trade under the symbol EOLS (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Evolus, Inc.

We are a global performance beauty company delivering breakthrough products with a customer-centric approach. Our primary market is the cash-pay aesthetic market, which consists of medical products that consumers pay for directly out of pocket. Our customers are aesthetic practitioners who are properly licensed to deliver our products. By avoiding the regulatory burdens that accompany reimbursed products and pursuing an aesthetic-only non-reimbursed product strategy, we believe that we create flexibility to deliver a unique value proposition to our customers. We utilize this flexibility to drive customer adoption efforts through programs such as our consumer loyalty program, co-branded marketing programs, promotional events and pricing strategies.

From the company's annual report filed with the US SEC: read the report

Evolus, Inc. timeline

4 events, 2012–2025
  1. 2012
  2. 🏁
    · approximate
    Founded
  3. 2013
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2018
  6. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 9 February 2018; shares registered for exchange trading on 1 February 2018.
  7. 2025
  8. 💰
    Record revenue of $297 million
    FY2025, the highest of the 7 years on record.

Events of Evolus, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$160 M$320 M$480 M$639 M2020202120222023202420252026

World rank over time

▼ down 333 places since 2020
2020-01-01: #12253#12,25320202021-01-01: #17685#17,68520212022-01-07: #15668#15,66820222022-12-25: #14106#14,10620222023-07-30: #11860#11,86020232024-01-05: #11576#11,57620242026-03-08: #7952#7,95220262026-08-01: #11961#11,96120262026-10-13: #12523#12,52320262026-10-16: #12586#12,5862026

Rank in USA: #2,663 (Jan 2020) · #3,616 (Jan 2021) · #3,305 (Jan 2022) · #2,895 (Dec 2022) · #2,561 (Jul 2023) · #2,399 (Jan 2024) · #1,419 (Mar 2026) · #2,487 (Aug 2026) · #2,510 (Oct 2026) · #2,536 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
1.5×
Price / book
—
Free cash flow yield
-9.1%
Net margin (TTM)
-9.6%
Operating margin
-11.0%
Return on equity
—
Liabilities / assets
110.2%
Net debt
$92M
Revenue growth
+11.6%
R&D / revenue
3.2%
Revenue per employee
$890 K
Profit per employee
$-155 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-47M—FY18Fiscal year ending Dec 2019: revenue $35M, net income $-90M$35MFY19Fiscal year ending Dec 2020: revenue $57M, net income $-163M$57MFY20Fiscal year ending Dec 2021: revenue $100M, net income $-47M$100MFY21Fiscal year ending Dec 2022: revenue $149M, net income $-74M$149MFY22Fiscal year ending Dec 2023: revenue $202M, net income $-62M$202MFY23Fiscal year ending Dec 2024: revenue $266M, net income $-50M$266MFY24Fiscal year ending Dec 2025: revenue $297M, net income $-52M$297MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$297M+11.6%$-33M$-52M-17.4%
Dec 2024$266M+31.8%$-34M$-50M-18.9%
Dec 2023$202M+36.0%$-49M$-62M-30.5%
Dec 2022$149M+49.1%$-65M$-74M-50.1%
Dec 2021$100M+76.3%$-44M$-47M-47.0%
Dec 2020$57M+61.9%$-153M$-163M-288.3%
Dec 2019$35M—$-99M$-90M-257.8%
Dec 2018——$-46M$-47M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-42M$3M$-46M$-0.80—
Dec 2024$-18M$1M$-19M$-0.81—
Dec 2023$-34M$0M$-34M$-1.08—
Dec 2022$-85M$2M$-87M$-1.33—
Dec 2021$-33M$0M$-34M$-0.94—
Dec 2020$-58M$1M$-59M$-4.83—
Dec 2019$-93M$0M$-94M$-3.19—
Dec 2018$-26M$0M$-26M$-1.92—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$325M
Net income, trailing 12 months
$-31M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $79M, net income $-7M$79MDec ’24Three months to Mar 2025: revenue $69M, net income $-19M$69MMar ’25Three months to Jun 2025: revenue $69M, net income $-17M$69MJun ’25Three months to Sep 2025: revenue $69M, net income $-16M$69MSep ’25Three months to Dec 2025 (from the annual report): revenue $90M, net income $0M$90MDec ’25Three months to Mar 2026: revenue $73M, net income $-11M$73MMar ’26Three months to Jun 2026: revenue $84M, net income $-8M$84MJun ’26Three months to Sep 2026: revenue $78M, net income $-13M$78MSep ’26

Latest quarter to Sep 2026: revenue $78M (+13.0% on a year earlier), net income $-13M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Evolus, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$297 M
Operating income
$-33 M
Net income
$-52 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$226 M
Total liabilities
$249 M
Total equity
$-23 M

As of December-2025

Top 100 institutional investors in Evolus, Inc.#

As of Sep 30, 2026
170 institutions held 50.7 M shares (about 76.6% of the shares outstanding) on Sep 30, 2026. The ten largest hold 48.6%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Evolus, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Nantahala Capital Management, LLC6,244,690-4,959,352 (-44.26%)9.43%$50 MNov 13, 2026
2BlackRock, Inc.5,315,493+474,665 (+9.81%)8.03%$43 MNov 13, 2026
3Soleus Capital Management, L.P.5,090,000+4,267,572 (+518.90%)7.69%$41 MNov 16, 2026
4Braidwell LP3,084,022-71,187 (-2.26%)4.66%$25 MNov 16, 2026
5Frazier Life Sciences Management, L.P.2,630,6650 (0.00%)3.97%$21 MNov 16, 2026
6Perceptive Advisors LLC2,459,2850 (0.00%)3.72%$20 MNov 16, 2026
7Vanguard Capital Management LLC2,261,324-101,569 (-4.30%)3.42%$18 MNov 13, 2026
8State Street Corp1,854,107+156,813 (+9.24%)2.80%$15 MNov 12, 2026
9Millennium Management LLC1,650,372-137,557 (-7.69%)2.49%$13 MNov 16, 2026
10Geode Capital Management, LLC1,580,338-28,056 (-1.74%)2.39%$13 MNov 6, 2026
11Pinnacle Associates LTD1,570,061+82,797 (+5.57%)2.37%$13 MOct 20, 2026
12Armistice Capital, LLC1,436,0000 (0.00%)2.17%$11 MNov 16, 2026
13Goldman Sachs Group Inc1,252,587+33,168 (+2.72%)1.89%$10 MNov 16, 2026
14Rice Hall James & Associates, LLC1,202,728-87,160 (-6.76%)1.82%$10 MNov 16, 2026
15Stonepine Capital Management, LLC971,622-618,540 (-38.90%)1.47%$8 MNov 13, 2026
16Renaissance Technologies LLC710,596+408,027 (+134.85%)1.07%$6 MNov 12, 2026
17Assenagon Asset Management S.A.651,816-1,164,544 (-64.11%)0.98%$5 MOct 15, 2026
18Vanguard Portfolio Management LLC636,789+91,087 (+16.69%)0.96%$5 MNov 13, 2026
19AWH Capital, L.P.625,000-625,000 (-50.00%)0.94%$5 MNov 16, 2026
20UBS Group AG537,392-215,287 (-28.60%)0.81%$4 MNov 10, 2026
21Charles Schwab Investment Management Inc529,075-1,768 (-0.33%)0.80%$4 MNov 16, 2026
22Northern Trust Corp480,305-16,713 (-3.36%)0.73%$4 MNov 16, 2026
23Soviero Asset Management, LP470,000-300,000 (-38.96%)0.71%$4 MNov 16, 2026
24Deutsche Bank AG\447,663-7,267 (-1.60%)0.68%$4 MNov 6, 2026
25Stifel Financial Corp416,979-6,195 (-1.46%)0.63%$3 MNov 12, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Evolus, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Vanguard Fiduciary Trust Co416,717-39,466 (-8.65%)0.63%$3 MNov 13, 2026
27CM Management, LLC380,000-20,000 (-5.00%)0.57%$3 MNov 12, 2026
28D. E. Shaw & Co., Inc.338,959+2,058 (+0.61%)0.51%$3 MNov 16, 2026
29Barclays PLC287,744+189,565 (+193.08%)0.43%$2 MNov 6, 2026
30Squarepoint Ops LLC248,003+50,295 (+25.44%)0.37%$2 MNov 9, 2026
31Wellington Management Group LLP209,507+39,573 (+23.29%)0.32%$2 MNov 16, 2026
32Quantinno Capital Management LP206,976+78,898 (+61.60%)0.31%$2 MNov 13, 2026
33Morgan Stanley189,850-47,709 (-20.08%)0.29%$2 MNov 13, 2026
34Prudential Financial Inc184,110New0.28%$1 MNov 16, 2026
35Two Sigma Investments, LP173,030New0.26%$1 MNov 16, 2026
36Bank of New York Mellon Corp165,802+2,953 (+1.81%)0.25%$1 MNov 5, 2026
37Angeles Wealth Management, LLC157,500+51,955 (+49.23%)0.24%$1 MOct 26, 2026
38KVP Capital Advisors, LP150,0000 (0.00%)0.23%$1 MNov 16, 2026
39Jacobs Levy Equity Management, Inc148,694New0.22%$1 MNov 16, 2026
40Potomac Capital Management, Inc.141,5000 (0.00%)0.21%$1 MNov 13, 2026
41Panagora Asset Management Inc139,213New0.21%$1 MNov 12, 2026
42Price T Rowe Associates Inc /MD/137,7610 (0.00%)0.21%$1 MNov 16, 2026
43Nuveen, LLC129,844-103,770 (-44.42%)0.20%$1 MNov 10, 2026
44AQR Capital Management LLC127,186+29,623 (+30.36%)0.19%$1 MNov 16, 2026
45Bank Of America Corp /de/123,717+50,485 (+68.94%)0.19%$1 MNov 16, 2026
46Russell Investments Group, Ltd.119,141+41,493 (+53.44%)0.18%$1 MNov 6, 2026
47National Philanthropic Trust116,720-83,280 (-41.64%)0.18%$1 MNov 13, 2026
48ADAR1 Capital Management, LLC100,0000 (0.00%)0.15%$1 MNov 16, 2026
49State Of Wisconsin Investment Board92,268+10,500 (+12.84%)0.14%$1 MNov 16, 2026
50LPL Financial LLC87,849+30,902 (+54.26%)0.13%$1 MNov 6, 2026
51Profund Advisors LLC70,711+56,901 (+412.03%)0.11%$1 MOct 29, 2026
52Susquehanna International Group, LLP70,466+37,913 (+116.47%)0.11%$1 MNov 16, 2026
53Rhumbline Advisers68,126-250 (-0.37%)0.10%$1 MNov 10, 2026
54Corient Private Wealth LP66,569+3,566 (+5.66%)0.10%$1 MNov 16, 2026
55GWN Securities Inc.64,041New0.10%$1 MNov 12, 2026
56Alliancebernstein L.P.62,040-7,400 (-10.66%)0.09%$0 MNov 16, 2026
57Pathstone Holdings, LLC61,492+44 (+0.07%)0.09%$0 MNov 13, 2026
58Krensavage Asset Management, LLC57,985-100,000 (-63.30%)0.09%$0 MNov 17, 2026
59State of Wyoming57,598+18,546 (+47.49%)0.09%$0 MOct 28, 2026
60Fuller & Thaler Asset Management, Inc.55,798+750 (+1.36%)0.08%$0 MNov 13, 2026
61Citadel Advisors LLC52,384-453,970 (-89.65%)0.08%$0 MNov 16, 2026
62Prelude Capital Management, LLC51,397+130 (+0.25%)0.08%$0 MNov 16, 2026
63Arrowstreet Capital, Limited Partnership50,911New0.08%$0 MNov 13, 2026
64Axq Capital, LP48,382+35,000 (+261.55%)0.07%$0 MNov 12, 2026
65HSBC Holdings PLC46,001+13,578 (+41.88%)0.07%$0 MNov 16, 2026
66Inceptionr LLC45,444+29,231 (+180.29%)0.07%$0 MNov 16, 2026
67Vanguard Global Advisers, LLC44,918+17,992 (+66.82%)0.07%$0 MNov 13, 2026
68Citigroup Inc43,547+549 (+1.28%)0.07%$0 MNov 4, 2026
69Integrated Quantitative Investments LLC42,773New0.06%$0 MNov 13, 2026
70Massachusetts Financial Services Co /ma/40,221New0.06%$0 MNov 12, 2026
71Jpmorgan Chase & Co39,417+6,068 (+18.20%)0.06%$0 MNov 12, 2026
72Wells Fargo & Company/mn38,361-46,387 (-54.74%)0.06%$0 MNov 16, 2026
73Caxton Associates LLP34,905New0.05%$0 MNov 13, 2026
74MetLife Investment Management, LLC34,324-756 (-2.16%)0.05%$0 MNov 16, 2026
75Invesco Ltd.33,960-1,533 (-4.32%)0.05%$0 MNov 12, 2026
76Ameriprise Financial Inc32,381-164 (-0.50%)0.05%$0 MNov 16, 2026
77Y-Intercept (Hong Kong) Ltd29,508New0.04%$0 MOct 16, 2026
78MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.28,633+1,287 (+4.71%)0.04%$0 MNov 16, 2026
79Tudor Investment Corp Et Al26,824-4,723 (-14.97%)0.04%$0 MNov 16, 2026
80Concurrent Investment Advisors, LLC26,342-1,487 (-5.34%)0.04%$0 MOct 16, 2026
81SEI Investments Co25,737-701 (-2.65%)0.04%$0 MNov 10, 2026
82Bender Robert & Associates25,070New0.04%$0 MOct 21, 2026
83Jump Financial, LLC24,838-14,597 (-37.02%)0.04%$0 MNov 13, 2026
84Bridgeway Capital Management, LLC24,582-418 (-1.67%)0.04%$0 MNov 16, 2026
85Empowered Funds, LLC24,582New0.04%$0 MNov 13, 2026
86Trexquant Investment LP23,839-122,486 (-83.71%)0.04%$0 MNov 16, 2026
87Creative Planning22,090-18,993 (-46.23%)0.03%$0 MNov 2, 2026
88Mercer Global Advisors Inc /adv21,509+9,173 (+74.36%)0.03%$0 MNov 16, 2026
89Chicago Partners Investment Group LLC21,347-901 (-4.05%)0.03%$0 MOct 27, 2026
90Strs Ohio18,500New0.03%$0 MOct 30, 2026
91Pure Financial Advisors, LLC17,8000 (0.00%)0.03%$0 MNov 16, 2026
92Envestnet Asset Management Inc17,398+6,389 (+58.03%)0.03%$0 MNov 16, 2026
93BNP Paribas Financial Markets16,777+5,203 (+44.95%)0.03%$0 MNov 12, 2026
94Manufacturers Life Insurance Company, The16,041+20 (+0.12%)0.02%$0 MNov 13, 2026
95Police & Firemen's Retirement System of New Jersey15,8330 (0.00%)0.02%$0 MNov 9, 2026
96OneDigital Investment Advisors LLC15,0000 (0.00%)0.02%$0 MNov 10, 2026
97New York State Common Retirement Fund14,1540 (0.00%)0.02%$0 MNov 17, 2026
98Graham Capital Management, L.P.13,908New0.02%$0 MNov 16, 2026
99Krilogy Financial LLC13,907+2,320 (+20.02%)0.02%$0 MOct 13, 2026
100Inscription Capital, LLC13,465New0.02%$0 MNov 2, 2026

All 170 institutional investors, with who bought and sold →

Mutual funds holding Evolus, Inc.#

88 funds hold shares worth $59 M (about 9.5% of the company). Since their previous reports 52 added shares and 16 sold, buying $7 M net.
Mutual funds holding Evolus, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.54 M$11 M1.7%<0.01%−7.3%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors1.54 M$11 M1.7%0.01%+16%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.770,279$5 M0.83%<0.01%+3.7%Jun 30, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors557,657$4 M0.60%0.03%+23%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC645,689$4 M0.70%0.01%+16%Jul 31, 2026
🇺🇸 State Street SPDR S&P Pharmaceuticals ETFSSGA Funds Management, Inc.325,329$2 M0.35%0.53%newJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC338,034$2 M0.37%<0.01%+39%May 31, 2026
🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc.309,043$2 M0.33%<0.01%−1.6%May 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.287,795$2 M0.31%0.01%+12%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors199,442$1 M0.22%0.09%+41%Jun 30, 2026
🇺🇸 iShares U.S. Pharmaceuticals ETFBlackRock Fund Advisors171,630$1 M0.19%0.10%−5.3%Jun 30, 2026
🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc.143,338$1 M0.16%<0.01%−0.8%May 31, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.144,427$1 M0.16%0.01%+17%Jul 31, 2026
🇺🇸 Clearwater Select Equity FundClearwater Management Co Inc.115,686$1 M0.13%0.16%no changeJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC113,928$1 M0.12%<0.01%no changeMay 31, 2026
🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC107,400$1 M0.12%<0.01%newJun 30, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC103,883$1 M0.11%0.01%+20%Jun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC97,736$1 M0.11%<0.01%+4.8%May 31, 2026
🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors72,169$1 M0.08%<0.01%+2.3%Jun 30, 2026
🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P.72,875$0 M0.08%0.05%−17%May 31, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC79,230$0 M0.09%0.01%+23%Jul 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC64,155$0 M0.07%0.01%+19%Jun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC55,645$0 M0.06%0.02%+31%Jun 30, 2026
🇺🇸 Tax-Managed U.S. Mid & Small Cap FundRussell Investment Management, LLC60,884$0 M0.07%0.02%no changeJul 31, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.52,226$0 M0.06%0.02%+10%May 31, 2026
🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc.45,976$0 M0.05%<0.01%+1.1%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC37,158$0 M0.04%<0.01%+8.6%May 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation35,000$0 M0.04%0.01%no changeJun 30, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.33,559$0 M0.04%<0.01%+187%Jun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC33,100$0 M0.04%0.01%no changeJun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC32,880$0 M0.04%0.01%+30%Jun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.30,735$0 M0.03%0.01%+7.8%Jun 30, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC35,311$0 M0.04%<0.01%+11%Jul 31, 2026
🇺🇸 T. Rowe Price Extended Equity Market Index FundT. Rowe Price Associates, Inc.27,500$0 M0.03%0.02%no changeJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.26,552$0 M0.03%<0.01%−19%Jun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.31,279$0 M0.03%<0.01%no changeJul 31, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC25,000$0 M0.03%0.12%newJun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC28,380$0 M0.03%0.01%+17%Jul 31, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company22,671$0 M0.02%0.01%no changeMay 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.21,334$0 M0.02%<0.01%−26%Jun 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC24,374$0 M0.03%<0.01%+3.0%Jul 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.20,100$0 M0.02%<0.01%+14%Jun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC19,890$0 M0.02%0.01%+159%Jun 30, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC22,153$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC18,429$0 M0.02%0.01%+28%Jun 30, 2026
🇺🇸 AQR Small Cap Multi-Style FundAQR CAPITAL MANAGEMENT, LLC18,314$0 M0.02%0.03%newJun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC16,585$0 M0.02%0.01%+13%Jun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC13,287$0 M0.01%0.04%+29%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS13,024$0 M0.01%0.01%+27%Jun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC12,388$0 M0.01%0.01%+16%Jun 30, 2026
🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors11,608$0 M0.01%<0.01%−0.8%Jun 30, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION11,000$0 M0.01%<0.01%no changeMay 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC10,044$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.9,322$0 M0.01%0.01%+21%Jun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC8,972$0 M<0.01%0.01%+19%Jun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.8,953$0 M<0.01%0.01%+50%Jun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC10,319$0 M0.01%0.01%+3.4%Jul 31, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC7,704$0 M<0.01%0.01%+22%Jun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC8,590$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC6,956$0 M<0.01%0.01%no changeJun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC6,954$0 M<0.01%0.01%+41%Jul 31, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC5,615$0 M<0.01%<0.01%+37%Jun 30, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management5,415$0 M<0.01%0.01%no changeJun 30, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC5,403$0 M<0.01%0.02%+36%Jun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.6,419$0 M<0.01%<0.01%+17%Jul 31, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC4,748$0 M<0.01%0.01%+15%Jun 30, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.4,870$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS5,360$0 M<0.01%0.01%+30%Jul 31, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC5,123$0 M<0.01%<0.01%+19%Jul 31, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC4,217$0 M<0.01%0.01%+31%Jun 30, 2026
🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC4,724$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Tiff Multi-Asset FundTIFF Advisory Services, LLC3,593$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC2,641$0 M<0.01%<0.01%+17%May 31, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC2,423$0 M<0.01%<0.01%−44%Jun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC2,258$0 M<0.01%<0.01%+56%Jun 30, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC2,084$0 M<0.01%<0.01%−35%May 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC2,064$0 M<0.01%<0.01%−36%May 31, 2026
🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC1,980$0 M<0.01%<0.01%−5.4%May 31, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.1,499$0 M<0.01%<0.01%−5.8%Jun 30, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC1,488$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC1,358$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC1,145$0 M<0.01%<0.01%+4.5%Jun 30, 2026
🇺🇸 TIAA Separate Account VA-1 - Stock Index AccountTeachers Advisors, LLC702$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Nuveen Life Stock Index FundTeachers Advisors, LLC533$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc.365$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Wilshire 5000 Index FundWilshire Advisors LLC316$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC291$0 M<0.01%<0.01%+3.9%Jul 31, 2026
🇺🇸 E*TRADE No Fee Total Market Index FundMorgan Stanley Investment Management Inc.37$0 M<0.01%<0.01%—Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 88 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Evolus, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$1.8 M
7 sales, 2 insiders
Net, 12 months
-$1.8 M
open market only
Insiders on file
22
since
$205 K-$6.1 M$0Dec 2023: bought $0 (0 trades), sold $823 K (2 trades)Dec 23Jan 2024: bought $0 (0 trades), sold $157 K (1 trades)Feb 2024: bought $0 (0 trades), sold $125 K (3 trades)FebMar 2024: bought $0 (0 trades), sold $1.9 M (4 trades)May 2024: bought $0 (0 trades), sold $772 K (6 trades)MayJun 2024: bought $0 (0 trades), sold $6.1 M (4 trades)Aug 2024: bought $0 (0 trades), sold $89 K (1 trades)AugSep 2024: bought $0 (0 trades), sold $49 K (1 trades)Dec 2024: bought $0 (0 trades), sold $156 K (3 trades)DecMar 2025: bought $0 (0 trades), sold $2.2 M (6 trades)May 2025: bought $0 (0 trades), sold $254 K (3 trades)MayJun 2025: bought $189 K (1 trades), sold $1.3 M (2 trades)Aug 2025: bought $205 K (1 trades), sold $43 K (1 trades)AugDec 2025: bought $0 (0 trades), sold $92 K (2 trades)Mar 2026: bought $0 (0 trades), sold $797 K (4 trades)MarSep 2026: bought $0 (0 trades), sold $950 K (1 trades)
Bought (open market)Sold (open market)Hover a month for the totals
Evolus, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed David MoatazediSee Remarks, DirectorSell-105,108$9.040$950 K499,592Form 4
filed Rui AvelarSee RemarksSell10b5-1 plan-3,119$4.750$15 K427,423Form 4
filed David MoatazediSee Remarks, DirectorSell10b5-1 plan-13,669$4.750$65 K604,700Form 4
filed David MoatazediSee Remarks, DirectorSell10b5-1 plan-116,720$4.890$571 K618,369Form 4
filed Rui AvelarSee RemarksSell10b5-1 plan-29,996$4.890$147 K430,542Form 4
filed David MoatazediSee Remarks, DirectorOption exercise10b5-1 plan+67,489——735,089Form 4
filed Rui AvelarSee RemarksOption exercise10b5-1 plan+8,804——460,538Form 4
filed Vikram MalikDirectorGrant or award+45,559——321,109Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Evolus, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
6.0 M
9.3% of shares · 9.38 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1.653-for-1 split

Trading halts

  • 2025-02-13 18:25 UTC, code T3, resumed 19:00 UTC

Fails to deliver

  • : 305,717 shares at $7.57
  • : 223 shares at $7.75
  • : 1,222 shares at $7.80
  • : 1,295 shares at $7.14
  • : 19,712 shares at $7.99

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Evolus, Inc. scorecard#

Passes 8 of the 19 checks that could be worked out: strongest in growth (5 of 6), weakest in valuation (1 of 5). Fiscal year 2025; market cap of Oct 16, 2026.

  • Valuation1 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • ✓Price to sales below its peers' median1.5×Price to sales 1.5× against Pharmaceutical's median of 3.5×.
    • ✗Free cash flow yield above 5%-9.1%Free cash flow is -9.1% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth5 of 6
    • ✓Revenue grew in the newest year11.6%Revenue up 11.6% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years26.0%26.0% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median26.0%26.0% a year against Pharmaceutical's median of 2.5% (65 companies).
    • ✗Earnings per share grew in the newest year-0.80 vs -0.81Diluted EPS -0.80 in fiscal 2025 against -0.81 the year before (report's currency).
    • ✓Net income higher than five years earlier-$52 M-$52 M in fiscal 2025 against -$163 M in 2020.
    • ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
  • Profitability1 of 4
    • ✗Profitable in the newest year-$52 MNet income -$52 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-11.0%-11.0% against Pharmaceutical's median of 1.8% (74 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-11.0%-11.0% in fiscal 2025 against -44.0% in 2022.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities1.9×Current ratio 1.90 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-1.69Z-score -1.69 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year4.0%Diluted shares up 4.0% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Evolus, Inc.'s statements, beside the median of Pharmaceutical.

Evolus, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-11.0%1.8%
Net margin-17.4%-1.5%
Revenue growth, 3 years a year26.0%2.5%
Revenue growth11.6%7.3%
Free cash flow margin-15.4%6.0%

2of 9on the Piotroski tests of financial strength

  • Net loss of $52 million, the 9th loss-making year in a row.
  • Free cash flow was negative: -$46 million.
  • Shareholders' equity is negative: -$23 million.
  • Revenue has grown 6 years in a row.

Evolus, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Evolus, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017
Income statement
Revenue29726620214910057350—
Cost of revenue1008465r59r44188.00—
Gross profit19718213890——270—
Research and development9.69.26.64.72.11.74.06.56.7
Selling, general and administrative2211981651421129811429—
General and administrative———————294.8
Operating expenses——————1264612
Total costs and expenses230217187r155r144210134——
Operating income−33−34−49−65−44−153−99−46−12
Interest and finance income———————0.20
Interest expense and finance costs2019149.11.4——0.90.0
Other non-operating income (expense)−0.50.10.7−0.00r−11−8.0−0.9—
Income before tax−51−50−62−74−47−163−105−47−12
Income tax0.70.70.20.10.00.1−150.1−7.3
Net income attributable to shareholders−52−50−62−74−47−163−90−47−4.5
Earnings per share, basic-0.80-0.81-1.08-1.33-0.94-4.83-3.19-1.92-0.27
Earnings per share, diluted-0.80-0.81-1.08-1.33-0.94-4.83-3.19-1.92-0.27
Shares, weighted average (basic)646257565034———
Shares, weighted average (diluted)646257565034282417
Balance sheet
Cash and cash equivalents54876354146103110930
Short-term investments————05.0200—
Receivables55483122159.7110—
Inventory271211191.83.46.40—
Other current assets3.71.22.41.7112.2r5.31.20.2
Current assets1431511121011791281529473
Property, plant and equipment5.43.22.12.61.41.30.900
Right-of-use (leased) assets7.17.25.81.92.73.44.10—
Goodwill212121212121212121
Other intangible assets484947495155605656
Total assets226233189178257209240172152
Accounts payable239.24.38.96.19.65.81.60.4
Current liabilities7563484758180245.3213
Long-term debt146122————740—
Lease liabilities (non-current)6.46.84.81.22.33.13.90r—
Total liabilities24922721015917628216187228
Retained earnings−661−609−559−497−423−376−213−123−76
Shareholders' equity−235.5−211882−737984−76
Total liabilities and equity226233189178257209240172152
Shares outstanding656358r565634342717
Cash-flow statement
Depreciation and amortization7.55.35.13.75.67.04.10.00.2
Share-based compensation212216119.6119.57.00.6
Cash from operating activities−42−18−34−85−33−58−93−26−13
Capital expenditure−3.4−1.5−0.5−1.6−0.4−0.8−0.3−0.00
Cash from investing activities−8.5−4.8−1.6−2.94.012−23−0.00
Debt issued—0500——740—
Debt repaid———00−0.5r−1.00—
Shares issued05100—073680
Cash from financing activities174745−4.1733813411913
Exchange-rate effect on cash0.3−0.5−0.1−0.30————
Change in cash−33248.9−9244−7.3—93−0.2
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Evolus, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Product revenue, net(total)$295 M99%
  • Jeuveau$272 M92%
  • Evolysse$23 M7.6%
  • Service revenue(total)$2 M0.8%

Business segments

  • Reportable$297 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Where Evolus, Inc. operates: 8 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 7 subsidiaries on file.

Evolus, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office—
🇦🇺 Australia1 subsidiary—
🇩🇪 Germany1 subsidiary—
🇮🇪 Ireland1 subsidiary—
🇳🇱 Netherlands1 subsidiary—
🇳🇿 New Zealand1 subsidiary—
🇪🇸 Spain1 subsidiary—
🇬🇧 UK1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Evolus, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$6.4 M
Mr. Moatazedi
Other top executives, average
$2.0 M
the CEO earned 3.1× this
$100 invested is now
$102
peer group: $120
Evolus, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Mr. Moatazedi$6.4 M−$746 K$2.0 M$102 (peers $120)
2024Chief executive$7.0 M$4.8 M$2.1 M$170 (peers $91)
2023Chief executive$11.2 M$13.6 M$2.7 M$162 (peers $92)
2022Chief executive$3.6 M$5.8 M$1.5 M$115 (peers $90)

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Evolus, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 8 · Material agreement 5 · New debt 2 · Shareholder vote 3 · Results announced 13

Evolus, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Material agreement8-K
Material agreement8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Material agreementNew debtResults announced8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Directors and officersResults announced8-K
Directors and officersShareholder vote8-K
Directors and officers8-K
Results announced8-K
Material agreementNew debt8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Directors and officersShareholder vote8-K
Results announced8-K
Directors and officers8-K
Material agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 4, 2026

Lobbying by Evolus, Inc.#

$35 K spent on lobbying the US Congress and federal agencies in 2021, most often on trade (domestic/foreign).

Lobbying, 2021
$35 K
#1,279 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2021
2026 so far
—
  • Trade (domestic/foreign)1 report

Lobbying firms hired in 2021

Carmen Group Incorporated $35 K

Evolus, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2021$35 K—1
2020$175 K—2

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Evolus Inc”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

H-1B hiring at Evolus, Inc.#

1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $167 K a year.

Certified, FY2026
1
#1,816 among companies on value.today
Worker positions
1
Median wage offered
$167 K
a year, full-time
Applications filed
1
Evolus, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
TECHNICAL LEAD, DATA ENGINEERINGData Scientists1$167 K

Where: Newport Beach, CA 1

Evolus, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202611$167 K1
FY202411$160 K1
FY202311$142 K1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Evolus, Inc.

FDA drug approvals: Evolus, Inc.#

1 approved applications held, 1 of them new molecular entities; 1 approvals and 0 new uses in 2019.

Approvals held
1
New molecular entities
1
New uses approved
0
efficacy supplements
Generics
0
0 new drugs, 1 biologics
Evolus, Inc.: latest FDA approvals
ApprovedDrugKind
2019-02-01Jeuveaunew moleculePrabotulinumtoxina-Xvfs · BLA761085Biologic (BLA)

Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (EVOLUS INC), so they follow acquisitions

Layoffs at Evolus, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
101
2020–2020
Latest
101 people
2020-04-16
Evolus, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2020···101········101
Evolus, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
effective 101 peopleLayoffWARN noticeOrange County, CaliforniaNotice list

Source: State WARN notices and SEC 8-K item 2.05

Discuss Evolus, Inc.#

2 automatic updates and 0 member comments. Sign in to comment and react.

  • Results announced on 4 November 2026automatic update · Nov 4, 2026

    Evolus, Inc. announced results on 4 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: revenue of $78 million (up 13% from a year earlier) and a net loss of $13 million.

  • Mutual funds: 88 funds hold $59 millionautomatic update · Jul 31, 2026

    88 mutual funds in 1 country hold shares of Evolus, Inc. worth $59 million, about 9.5% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 52 funds added shares and 16 sold; on balance they bought $7 million. Share splits are not counted as trading.

How Evolus, Inc. compares in Pharmaceutical

  • Market cap$501 M · higher than 35% of 393
  • Revenue$297 M · higher than 37% of 324
  • Net margin-9.6% · higher than 18% of 313
  • Revenue growth11.6% · higher than 64% of 107
  • Price / sales1.5× · lower than 71% of 219
  • FCF yield-9.1% · higher than 25% of 69

Peer comparison · Pharmaceutical

CompanyMarket capP/ENet marginRev. growth
Evolus, Inc.🇺🇸$501 M—-9.6%+11.6%
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Amgen Inc.🇺🇸$249.2 B26.5×24.1%+9.9%
AstraZeneca PLC🇬🇧$242.6 B23.7×17.4%+8.6%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 16, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Evolus, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Evolus, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Evolus, Inc.? Suggest a correction